FONT-SIZE Plus   Neg

FDA Accepts Actelion's NDA For Macitentan

Actelion Pharmaceuticals Ltd. (ALIOF.PK, ATLN.L) Friday said its New Drug Application, or NDA, for macitentan has been accepted by The U.S. Food and Drug Administration.

Macitentan is registered under the name Opsumit, and is used for the treatment of patients with pulmonary arterial hypertension.

Pulmonary arterial hypertension is a chronic disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs of an affected individual.

In a random, pivotal, long-term Phase III study, Macitentan was found to reduce the risk of morbidity and mortality event over the treatment period versus placebo.

For patients in the 10 mg and 3 mg dose group, risk was reduced by 45 percent and 30 percent, respectively. Meanwhile, nasopharyngitis, headache and anemia were the most common adverse events associated with the use of macitentan.

The review period is expected to last 12 months from the date of NDA submission.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
AT&T announced a definitive agreement to purchase Time Warner in a stock-and-cash transaction valued at $107.50 per share. This purchase price implies a total equity value of $85.4 billion and a total transaction value of $108.7 billion, including Time Warner's net debt. AT&T expects the deal to close before year-end 2017. Chipmaker Qualcomm is reportedly in talks with NXP Semiconductor NV (NXPI) for a possible acquisition, reports said. According to Bloomberg, negotiations are on with a probable price of $110 t $120 per NXP share. The deal would value NXP at around $34.7 billion. Regulators have confirmed the eleventh U.S. fatality linked to Takata Corp.'s defective air bag inflators. The National Highway Traffic Safety Administration or NHTSA said Thursday that a crash fatality in Riverside County, California, was tied to the rupture of a recalled Takata air bag inflator.
comments powered by Disqus
Follow RTT